Clinical applications of circulating tumor DNA (ctDNA) as biomarker in gastric cancer

Abstract

Gastric cancer is one of the most prevalent malignancies of the gastrointestinal tract. Worldwide, it ranks as the fourth most commonly diagnosed cancer and the third leading cause of cancer-related mortality. A variety of diagnostic approaches are used for the detection of gastric cancer. Early diagnosis of gastric cancer is crucial, as timely treatment can significantly improve patient prognosis. Detection and monitoring of circulating tumor DNA (ctDNA) provide valuable clinical information while minimizing the need for invasive procedures, such as tissue biopsy. These ctDNAs have been identified as reliable and accurate biomarkers for gastric cancer. The application of ctDNA in gastric cancer plays a significant role in the early diagnosis, detection, and monitoring of minimal residual disease, as well as in the clinical management of advanced-stage disease.

Keywords

liquid biopsy / biomarkers in gastric cancer / next-generation DNA sequencing / gastric cancer / ctDNA

References

[1] Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14: 26-38.

[2] Uguztemur E, Oztürk B. Impact of Treatment Modalities on Locally Advanced Gastric Cancer-Real-World Data. Curr Oncol. 2025; 32: 463.

[3] Li Z, Song M, Han S, Jin C, Yang J. The prognostic role of circulating tumor cells in gastric cancer: A meta-analysis. Front Oncol. 2022; 12: 963091.

[4] Mencel J, Slater S, Cartwright E, Starling N. The Role of ctDNA in Gastric Cancer. Cancers (Basel). 2022; 14: 5105.

[5] Businello G, Galuppini F, Fassan M. The impact of recent next generation sequencing and the need for a new classification in gastric cancer. Best Pract Res Clin Gastroenterol. 2021; 50-51: 101730.

[6] Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024; 9: 336.

[7] Kim IH. Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond. J Gastric Cancer. 2024; 24: 29-56.

[8] Aravanis AM, Lee M, Klausner RD. Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Cell. 2017; 168: 571-4.

[9] Donaldson J, Park BH. Circulating Tumor DNA: Measurement and Clinical Utility. Annu Rev Med. 2018; 69: 223-34.

[10] Chen W, Yan H, Li X, Ge K, Wu J. Circulating tumor DNA detection and its application status in gastric cancer: a narrative review. Transl Cancer Res. 2021; 10: 529-36.

[11] Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. J Surg Oncol. 2022; 125: 1104-9.

[12] Jagtap SV, Jagtap SS. Methylation of BRCA1 promoter in sporadic breast cancer. Indian J Med Res. 2023; 158: 85-7.

[13] Fu DG. Epigenetic alterations in gastric cancer (Review). Mol Med Rep. 2015; 12: 3223-30.

[14] Li TT, Liu H, Yu J, Shi GY, Zhao LY, Li GX. Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. World J Gastroenterol. 2018; 24: 2236-46.

[15] Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seeber A, et al. The Emerging Role of Liquid Biopsy in Gastric Cancer. J Clin Med. 2021; 10: 2108.

[16] Zhao CF, Li QW, Ye SY, Chen LW, Xu ZF. Innovative insights and future research directions in gastric cancer through single-cell RNA sequencing. World J Gastrointest Oncol. 2025; 17: 103808.

[17] Rays A, Fedyanin M, Popov D, Pokataev I, Lyadova M, Zhukova L, et al. Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study. Explor Dig Dis. 2025; 4: 100568.

[18] Deng Q, Jiang B, Yan H, Wu J, Cao Z. Circulating tumor cells in gastric cancer: developments and clinical applications. Clin Exp Med. 2023; 23: 4385-99.

[19] Jiang C, Zhang J, Wang W, Shan Z, Sun F, Tan Y, et al. Extracellular vesicles in gastric cancer: role of exosomal lncRNA and microRNA as diagnostic and therapeutic targets. Front Physiol. 2023; 14: 1158839.

[20] Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020; 11: 3475.

[21] Liu Z, Shi Z, Jiang W, Shen Z, Chen W, Shen K, et al. Circulating tumor DNA analysis for prediction of prognosis and molecular insights in patients with resectable gastric cancer: results from a prospective study. MedComm (2020). 2025; 6:e70065.

[22] Sahwan O, Batha L, Jamal F, Sonbol MB. Circulating Tumor DNA (ctDNA) in Gastroesophageal Adenocarcinoma (GEA): Evidence and Emerging Applications. Cancers (Basel). 2025; 17: 3692.

[23] Krishnan T, Solar Vasconcelos JP, Titmuss E, Vanner RJ, Schaeffer DF, Karsan A, et al. Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer Res Commun. 2025; 5: 66-73.